Involved in SBIR over most of the firm's operation, Gliatech was organized around all forms of biomaterials and therapeutics basedon glial cells. Also called neuroglia, glial are non-neuronal cells in the central nervous system (brain and spinal cord) and the peripheral nervous system peforming the function of maintaining homeostasis, forming myelin, and providing support and protection for neurons. Thought he firm raised signiicant funds and acheived Publicly funded status, the company ceased its operations in 2002. Previously, the company developed several biosurgery products - proprietary, resorbable, carbohydrate polymer medical devices to inhibit scarring and adhesions following surgery. The firm's pharmaceutical product candidates included small molecule drugs to modulate the cognitive state of the nervous system and proprietary monoclonal antibodies to treat inflammatory disorders. In May 2002, Gliatech Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio. In Jan 2003, Wright Medical Wright Medical purchased all assets related to Gliatech's (biomaterials and therapeutics based on glial cells) Adcon line of resorbable biopolymer gels.
